Scilex Holding Company announced a claim process for its Dream Bowl 2026 Meme Coin on December 23 2025. Shareholders of record as of November 25 2025 will be able to claim their allocated tokens following the December 24 distribution date through the company’s website, www.dreambowlcoin.com.
The announcement comes amid a period of financial distress for Scilex. In the third quarter of 2025 the company reported a net loss of $257.23 million, a sharp increase from the $4.39 million loss in the same quarter a year earlier, and sales fell to $10.56 million from $14.44 million in Q3 2024. The company also disclosed substantial doubt about its ability to continue as a going concern.
Scilex’s $150 million investment in Datavault AI, completed in September 2025, was paid in Bitcoin and was structured in two tranches: an initial $8.07 million closing on September 26 2025 and a second $141.93 million pending shareholder approval. The investment was intended to fund Datavault’s supercomputing infrastructure and data‑exchange expansion, positioning Scilex to leverage AI and blockchain technology for future growth.
The Dream Bowl 2026 Meme Coin is a digital collectible tied to the Dream Bowl XIV event on January 11 2026. It does not confer equity, voting rights, or monetary payments, and its fair‑market value was stated as $0.0000014 as of November 19 2025. The coin is intended for personal, non‑commercial use and will be tradeable on Datavault’s Information Data Exchange.
In a statement, Scilex CEO Henry Ji, Ph.D., said, “Datavault AI’s cutting‑edge technologies align perfectly with the biotech sector’s need for advanced data analytics, AI‑driven insights, and super‑computing power. This investment reflects our belief in Datavault’s ability to transform markets where trust and precision are critical.”
The launch of the meme coin marks a bold, speculative move that underscores Scilex’s shift toward digital assets as a potential revenue source. While the initiative may attract regulatory scrutiny and market volatility, it also signals the company’s willingness to explore alternative value‑creation channels amid ongoing biopharma challenges.
Investor sentiment has been cautious. The company’s recent earnings miss and going‑concern disclosure have weighed on confidence, and the market has responded with a muted reaction to the meme‑coin announcement, reflecting uncertainty about the long‑term viability of this new strategy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.